Sandostatin

— THERAPEUTIC DISORDERS TREATED —
  • Cytoprotective and supportive care agents
  • Pituitary disorders
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Sandostatin Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Octreotide acetate 50mcg, 100mcg, 500mcg; per vial; soln for IV or SC inj; contains mannitol, phenol.

    Pharmacological Class

    Somatostatin analogue.

    See Also

    How Supplied

    Ampules 50mcg/mL, 100mcg/mL, 500mcg/mL (1mL)—10; LAR kit—1 (6mL vial w. supplies)

    Manufacturer

    Novartis Pharmaceuticals Corp

    Sandostatin Indications

    Indications

    Severe diarrhea and flushing due to metastatic carcinoid tumors. Profuse watery diarrhea due to vasoactive intestinal peptide-secreting tumors (VIPomas).

    Sandostatin Dosage and Administration

    Adult

    Give by IV infusion over 15–30 minutes, IV push over 3 minutes, or deep SC (intrafat) inj. Carcinoid tumors: 100–600mcg/day in 2–4 divided doses for first 2 weeks; usual maintenance: 450mcg/day; max 1500mcg/day. VIPomas: Initially 200–300mcg/day in 2–4 divided doses for first 2 weeks; max 750mcg/day.

    Children

    Not recommended.

    Sandostatin Contraindications

    Not Applicable

    Sandostatin Boxed Warnings

    Not Applicable

    Sandostatin Warnings/Precautions

    Warnings/Precautions

    Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Carcinoid tumors: monitor 5-HIAA, plasma serotonin, plasma Substance P. VIPomas: perform baseline and periodic total and/or free T4 measurements with chronic therapy. Monitor thyroid function, gallbladder, glucose, vitamin B12. Pregnancy. Nursing mothers.

    Sandostatin Pharmacokinetics

    See Literature

    Sandostatin Interactions

    Interactions

    Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance. May interfere with efficacy of lutetium Lu 177 dotatate inj; discontinue octreotide at least 24 hours prior to each lutetium Lu dose.

    Sandostatin Adverse Reactions

    Adverse Reactions

    Gallbladder abnormalities (eg, gallstones, biliary sludge), GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, headache, dizziness, pancreatitis, back pain, inj site pain.

    Sandostatin Clinical Trials

    See Literature

    Sandostatin Note

    Not Applicable

    Sandostatin Patient Counseling

    See Literature

    Sandostatin Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Octreotide acetate 50mcg, 100mcg, 500mcg; per vial; soln for IV or SC inj; contains mannitol, phenol.

    Pharmacological Class

    Somatostatin analogue.

    See Also

    How Supplied

    Ampules 50mcg/mL, 100mcg/mL, 500mcg/mL (1mL)—10; LAR kit—1 (6mL vial w. supplies)

    Manufacturer

    Novartis Pharmaceuticals Corp

    Sandostatin Indications

    Indications

    Acromegaly unresponsive to or that cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses.

    Sandostatin Dosage and Administration

    Adult

    Give by IV infusion over 15–30 minutes, IV push over 3 minutes, or deep SC (intrafat) inj. Initially 50mcg 3 times daily. Usual maintenance: 100micrograms 3 times daily; max 500mcg 3 times daily. Reevaluate every 6 months. Pituitary irradiation recipients: withdraw therapy for 4 weeks once yearly to assess disease activity; resume if GH or IGF-1 levels increase or signs/symptoms recur.

    Children

    Not recommended.

    Sandostatin Contraindications

    Not Applicable

    Sandostatin Boxed Warnings

    Not Applicable

    Sandostatin Warnings/Precautions

    Warnings/Precautions

    Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Monitor growth hormone, IGF-1 levels, thyroid function, gallbladder, glucose, vitamin B12. Discontinue and treat if cholelithiasis complications are suspected. Pregnancy. Nursing mothers.

    Sandostatin Pharmacokinetics

    See Literature

    Sandostatin Interactions

    Interactions

    Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance. May interfere with efficacy of lutetium Lu 177 dotatate inj; discontinue octreotide at least 24 hours prior to each lutetium Lu dose.

    Sandostatin Adverse Reactions

    Adverse Reactions

    Gallbladder abnormalities (eg, gallstones, biliary sludge), GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, headache, dizziness, pancreatitis, back pain, inj site pain.

    Sandostatin Clinical Trials

    See Literature

    Sandostatin Note

    Not Applicable

    Sandostatin Patient Counseling

    See Literature

    • Latest News Your top articles for Sunday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More